Detalhe da pesquisa
1.
DHH is an independent prognosticator of oncologic outcome of clear cell renal cell carcinoma.
J Urol;
192(6): 1842-8, 2014 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25046620
2.
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.
J Pathol;
227(1): 53-61, 2012 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22294438
3.
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.
Genome Med;
11(1): 8, 2019 02 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30777124
4.
ONECUT2 is a driver of neuroendocrine prostate cancer.
Nat Commun;
10(1): 278, 2019 01 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30655535
5.
Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Oncotarget;
6(25): 21522-32, 2015 Aug 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26041878
6.
Crosstalk between nuclear MET and SOX9/ß-catenin correlates with castration-resistant prostate cancer.
Mol Endocrinol;
28(10): 1629-39, 2014 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25099011
7.
Prostate stromal cells express the progesterone receptor to control cancer cell mobility.
PLoS One;
9(3): e92714, 2014.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24664419
8.
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer.
Genome Biol;
15(8): 426, 2014 Aug 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25155515
9.
Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach.
PLoS One;
8(3): e59536, 2013.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23555699
10.
Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development.
J Natl Cancer Inst;
105(19): 1463-73, 2013 Oct 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24052624